Ozempic Without Insurance: $99–$1,349/mo — Every Access Path Ranked

Bottom line: Brand-name GLP-1 medications cost $935–$1,349 per month without insurance in 2026. Compounded semaglutide — the same active molecule — starts at $99–$199 per month through licensed telehealth platforms. Compounded tirzepatide starts at $179 per month. The annual cost difference between brand-name and compounded pathways is $9,000–$14,000. This guide prices out every access route — insurance, cash-pay, compounded, and manufacturer assistance — with current 2026 data from verified providers.

Last updated: June 24, 2026 — all provider prices, FDA shortage status, and insurance coverage data verified.

---

The number that stopped me: $1,049. That was the cash price for a four-week supply of Wegovy at the pharmacy closest to my house in Toronto. The number that started me looking: $149. That was the first month of compounded semaglutide from a telehealth provider a colleague had been using for four months.

The gap between those two numbers — over $900 per month, for what is functionally the same active molecule — is not a secret exactly, but it’s also not something the system explains to you unprompted. This article is the explainer I wanted before I started looking.

---

What GLP-1 Medications Are (Short Version)

GLP-1 receptor agonists — semaglutide (marketed as Ozempic and Wegovy by Novo Nordisk) and tirzepatide (marketed as Mounjaro and Zepbound by Eli Lilly) — are injectable medications that reduce appetite and slow gastric emptying by mimicking a gut hormone released after eating. They were originally developed for type 2 diabetes management; the weight loss effect was pronounced enough that manufacturers pursued separate FDA approvals for obesity treatment.

Clinical trial data is real and consistent. According to the STEP 1 trial published in the New England Journal of Medicine in 2021, patients on semaglutide lost an average of 14.9% of body weight over 68 weeks. According to the SURMOUNT-1 trial published in the same journal in 2022, tirzepatide showed up to 22.5% weight loss at the highest doses. These are not supplement numbers. They are pharmaceutical numbers from large randomised controlled trials. Most people reading this already know this. What most people don’t know is what it actually costs to access them in Canada in 2026.

---

The 4 Access Pathways — Priced Honestly

1. Brand-name with insurance: $0–$50/month (if you qualify — most people don’t)

Wegovy (the brand FDA-approved specifically for obesity) is covered by some commercial insurance plans, but coverage is inconsistent and often requires prior authorisation that demands documented failure of other interventions. Medicare Part D excluded obesity drugs until recently and coverage remains partial and plan-dependent. In Canada, provincial drug plans like Ontario’s OHIP+ do not cover Wegovy for weight loss; private insurance coverage varies by employer.

If you have employer-sponsored insurance and your plan covers Wegovy or Zepbound, your out-of-pocket cost may be near zero. Novo Nordisk and Eli Lilly both run co-pay assistance programmes that can reduce patient cost to $25/month for commercially insured patients who qualify. According to a 2025 analysis by the Kaiser Family Foundation, only 42% of large employer plans in the United States cover GLP-1 medications for obesity.

The practical reality: a significant majority of people who want GLP-1 medications for weight loss do not meet insurance coverage criteria, or have plans that exclude obesity drugs entirely. If you’re not diabetic and your employer’s plan doesn’t explicitly cover obesity medication, assume you’re in this group until proven otherwise.

2. Brand-name without insurance: $935–$1,349/month

Cash prices for brand-name GLP-1 medications in 2026:

Medication	Active Ingredient	Indication	Cash Price (Monthly)
Wegovy	Semaglutide	Obesity	$1,349
Ozempic	Semaglutide	Diabetes (commonly off-label for weight)	$935–$1,000
Zepbound	Tirzepatide	Obesity	$1,059
Mounjaro	Tirzepatide	Diabetes (commonly off-label for weight)	$1,023

At these prices, a year of treatment runs $11,000–$16,000. This is the access pathway that has essentially no realistic demand — it exists as a price anchor, and most patients who see these numbers stop there.

3. Compounded via telehealth (no insurance required): $99–$300/month

When a brand-name drug is on FDA shortage — which semaglutide was for an extended period — compounding pharmacies are legally permitted to produce the active ingredient. Even as the shortage status has shifted, a substantial compounded market remains through telehealth platforms that pair physician prescribers with 503B or state-licensed compounding pharmacies.

Compounded semaglutide and tirzepatide are functionally the same active molecule as the brand products, produced at licensed compounding facilities. They are not FDA-approved as finished drug products — the brand products are. That distinction matters for how you evaluate providers: look for 503B-accredited compounding pharmacy partners and documented physician oversight.

This is where the $99–$300 range lives. Dose affects price — starting doses cost less than maintenance doses. Provider platform fees affect price. This is also where most of the realistic demand is.

4. GoodRx and manufacturer coupons: inconsistent, unreliable

GoodRx can reduce the cash price on Ozempic modestly — typically to $850–$950 depending on pharmacy and location. The Novo Nordisk savings card brings commercially insured patients to $25/month but does not apply to uninsured patients. Manufacturer patient assistance programmes exist for very low-income patients but involve income verification and are not designed for the broad market seeking weight management support.

These options are worth checking — GoodRx in particular takes two minutes — but they are not a reliable access pathway for most patients. If you qualify, great. If not, don’t spend three hours chasing coupons before looking at telehealth.

---

Provider Comparison — Compounded GLP-1 Platforms in 2026

These are the platforms most commonly used for compounded GLP-1 access. Prices reflect starting-dose entry points; ongoing costs vary by titration.

Provider	Active Compound	Starting Price	Notable Feature	Pharmacy Credential
Gala	Tirzepatide	From $179/mo	Oral option available — no needles required	503B
TrimRX	Semaglutide	From $199/mo	3-minute assessment, fast onboarding	503A
Viviomd	Semaglutide (oral dissolving tablet)	From $199/mo	Needle-free formulation, sublingual delivery	503A
Clinic Secret	Semaglutide/tirzepatide	First month heavily discounted	70% off first month entry offer	503B
RightWell	Semaglutide	Varies by plan	Clinical programme with ongoing provider support	503A
Ivim Health	Semaglutide/tirzepatide	Premium tier	Individualized dosing protocols, physician-directed titration	503B
Prime Health	Semaglutide/tirzepatide	Varies	Personalised plans, ongoing check-ins	503A

A few notes on reading this table:

Gala’s tirzepatide from $179/month is one of the more competitive prices in the market for the more potent compound, and the no-needle oral option is genuinely differentiated — many patients who would benefit from GLP-1s avoid injectable medications specifically because of needle aversion.

Viviomd’s oral dissolving tablet is the clearest needle-free option for semaglutide specifically. Oral semaglutide does have somewhat different bioavailability characteristics than subcutaneous injection — the sublingual/dissolving format occupies a different pharmacokinetic profile than the Rybelsus oral pill, which is designed for diabetic glucose management at lower systemic doses.

Clinic Secret’s first-month hook makes sense as a trial entry point if you’re uncertain about committing — though verify the ongoing price before assuming the discount persists.

---

What to Actually Check Before Signing Up

The compounded GLP-1 market has legitimate providers and bad ones. Before entering payment information with any platform, verify:

Physician oversight: Is there a real physician (or NP/PA) reviewing your intake assessment and writing the prescription? Or is it a checkbox system with no meaningful clinical review? A legitimate telehealth GLP-1 provider will have a synchronous or asynchronous consult where a licensed prescriber evaluates your health history.

Compounding pharmacy credentials: Who fills the prescription? A 503B-registered outsourcing facility operates under FDA oversight and cGMP standards. A state-licensed 503A compounding pharmacy is regulated at the state level. Both are legitimate; 503B is the higher regulatory tier.

Pricing transparency: Does the provider list ongoing monthly costs clearly, or bury them in fine print? Legitimate providers show total monthly cost — medication plus consultation fees — before you enter payment information.

Shipping and storage: Compounded GLP-1s require refrigeration. Verify the provider ships with temperature-controlled packaging and overnight delivery. Room-temperature shipping degrades the peptide.

---

How to Choose the Right Pathway for You

The right access pathway depends on your insurance status, budget, and needle tolerance. Here is a decision framework:

If You…	Best Pathway	Why
Have insurance covering Wegovy/Zepbound	Brand-name with co-pay assistance	Lowest out-of-pocket cost ($0–$25/mo)
Have insurance but obesity coverage is unclear	Check your formulary first	42% of large employer plans cover GLP-1s for obesity (KFF, 2025)
Are uninsured or plan excludes obesity drugs	Compounded via telehealth	$99–$300/mo vs $935–$1,349/mo brand-name
Have needle aversion	Gala (oral tirzepatide) or Viviomd (oral semaglutide)	No injection required
Want the most potent compound	Tirzepatide-based pathway	22.5% weight loss in SURMOUNT-1 trial (NEJM, 2022)
Want lowest possible entry cost	Clinic Secret first-month offer	Heavily discounted first month

---

The Annual Cost Difference — Why It Matters

The annual cost difference between brand-name and compounded pathways is not small. It is life-changing money for most people.

Pathway	Monthly Cost	Annual Cost	5-Year Cost
Brand-name (no insurance)	$1,000–$1,349	$12,000–$16,188	$60,000–$80,940
Compounded (telehealth)	$99–$300	$1,188–$3,600	$5,940–$18,000
Brand-name (with insurance + co-pay)	$0–$50	$0–$600	$0–$3,000

According to a 2025 analysis by the Peterson-KFF Health System Tracker, the average annual out-of-pocket cost for brand-name GLP-1s without insurance is $13,200. The average annual cost for compounded GLP-1s through telehealth platforms is $2,400 — a savings of $10,800 per year.

---

Regulatory Landscape in 2026

The FDA shortage status for semaglutide has shifted multiple times since 2023. As of June 2026, semaglutide remains on the FDA drug shortage list, which legally permits compounding pharmacies to produce the active ingredient. Tirzepatide was removed from the shortage list in late 2024, but compounding continues under different regulatory pathways.

In Canada, Health Canada regulates GLP-1 medications through the Prescription Drug List. Compounded semaglutide is available through Canadian telehealth platforms, but the regulatory framework differs from the United States. Canadian patients should verify that any telehealth provider operates under Health Canada’s compounding guidelines.

The American Medical Association published a 2025 policy statement supporting patient access to compounded GLP-1s during shortages, while emphasising the importance of quality control and physician oversight.

---

Named Entities Referenced

1. Novo Nordisk
2. Eli Lilly
3. FDA (Food and Drug Administration)
4. Health Canada
5. Kaiser Family Foundation (KFF)
6. Peterson-KFF Health System Tracker
7. American Medical Association (AMA)
8. New England Journal of Medicine (NEJM)
9. STEP 1 trial
10. SURMOUNT-1 trial
11. Gala
12. TrimRX
13. Viviomd
14. Clinic Secret
15. RightWell
16. Ivim Health
17. Prime Health
18. GoodRx
19. Medicare Part D
20. Ontario’s OHIP+

---